About Eiger BioPharmaceuticals, Inc
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California. Address: 2155 Park Boulevard, Palo Alto, CA, United States, 94306
Eiger BioPharmaceuticals, Inc News and around…
Latest news about Eiger BioPharmaceuticals, Inc (EIGR) common stock and company :
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)issued a positive ...
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the European Commission approve Zokinvy, a first-in-class breakthrough therapy for Hutchinson-Gilford progeria syndrome (HGPS) and pr
The analysts covering Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) delivered a dose of negativity to shareholders...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Veru Suggested By FDA To ...
Eiger Biopharmaceuticals Inc. ("Eiger", Nasdaq: EIGR) and AnGes Inc. ("AnGes", TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan.
In trading on Monday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed above their 200 day moving average of $6.51, changing hands as high as $7.31 per share. Eiger BioPharmaceuticals Inc shares are currently trading up about 13.1% on the day..
Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders will doubtless be very grateful to see the share price up...
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported that the Compensation Committee of Eiger's Board of Directors granted stock options to purchase an aggregate of 290,000 shares of Eiger's common stock to two newly hired employees. The stock options were granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.12 per unit.
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data demonstrating that treatment with avexitide significantly reduced the likelihood of fasting and protein-induced hypoglycemia in patients with congenital hyperinsulinism (HI).
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update.
In trading on Monday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed below their 200 day moving average of $6.64, changing hands as low as $6.60 per share. Eiger BioPharmaceuticals Inc shares are currently trading off about 6.4% on the day..
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced the appointments of Christopher Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs.
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership ...
Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 83.2% to $0.4348 after the company reported FY21 results. Allego N.V. (NASDAQ: ...
U.S. stocks traded slightly higher this morning following the release of weekly jobless claims data on Thursday. Following the market ...
Eiger BioPharmaceuticals Inc(NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in ...
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The ...
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50% (primary endpoint) and death by 60% in the Phase 3 TOGETHER study, a multi-center, randomized, double-blind, p
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets ...
Because, unfortunately, nature does not cure disease, even though the words of French philosopher and historian Voltaire would have you believe otherwise: "The art of medicine consists of amusing the patient while nature cures the disease," Voltaire had once famously said. TheStreet has compiled a list of some of the most expensive drug treatments in the world that cure diseases ranging from progeria, when infants start to look elderly to spinal muscular atrophy, neuroblastoma and a rare blood disorder. Swiss pharmaceutical giant Novartis apparently sells the most expensive drug in the world that costs $2.1 million.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19.
The analysts covering Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) delivered a dose of negativity to shareholders...
The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
According to data from Benzinga Pro, during Q4, Eiger BioPharmaceuticals's (NASDAQ:EIGR) reported sales totaled $3.36 million. Despite a ...
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf ...
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:01 PM. Here's what ...
Eiger BioPharmaceuticals, Inc (EIGR) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
